{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:15:32Z","timestamp":1783329332372,"version":"3.54.6"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009769","name":"David F and Margaret T Grohne Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA175795"],"award-info":[{"award-number":["R01CA175795"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["P50CA186781"],"award-info":[{"award-number":["P50CA186781"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201226","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:17:31Z","timestamp":1778109451000},"page":"201226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Endothelial injury is a central driver of systemic IFN-\u03b2 toxicity and is reversible through Jak inhibition"],"prefix":"10.1016","volume":"34","author":[{"given":"Lianwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Jenks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Nace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-7721","authenticated-orcid":false,"given":"Kah-Whye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201226_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201226_bib2","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201226_bib3","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"Interferome v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201226_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201226_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omton.2026.201226_bib6","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"INTERFEROME v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201226_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.omton.2026.201226_bib8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.1990.8.5.881","article-title":"Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma","volume":"8","author":"Kinney","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201226_bib9","first-page":"3990","article-title":"A phase I study of recombinant interferon-beta in patients with advanced malignant disease","volume":"5","author":"Ravandi","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201226_bib10","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of IFN-beta Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma","volume":"69","author":"Willmon","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201226_bib11","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201226_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cgt.2012.14","article-title":"Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta","volume":"19","author":"Naik","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2026.201226_bib13","first-page":"1508","article-title":"Systemic AAV9-IFNbeta gene delivery treats highly invasive glioblastoma","volume":"18","author":"GuhaSarkar","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201226_bib14","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2012.70","article-title":"Curative one-shot systemic virotherapy in murine myeloma","volume":"26","author":"Naik","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201226_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2013.11.010","article-title":"Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer","volume":"132","author":"Liu","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omton.2026.201226_bib16","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201226_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN beta-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum Gene Ther Cl Dev"},{"key":"10.1016\/j.omton.2026.201226_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/humc.2017.015","article-title":"Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV","volume":"28","author":"Velazquez-Salinas","year":"2017","journal-title":"Hum Gene Ther Cl Dev"},{"key":"10.1016\/j.omton.2026.201226_bib19","first-page":"3268","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201226_bib20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/mt.2016.167","article-title":"Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201226_bib21","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/nprot.2007.471","article-title":"Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection","volume":"2","author":"Bell","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omton.2026.201226_bib22","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","article-title":"Measles virus spread and pathogenesis in genetically modified mice","volume":"72","author":"Mrkic","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201226_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrclinonc.2010.87","article-title":"Therapy with azanucleosides for myelodysplastic syndromes","volume":"7","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201226_bib24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201226_bib25","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s10620-012-2553-1","article-title":"Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity","volume":"58","author":"Fontana","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.omton.2026.201226_bib26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00002018-200326110-00006","article-title":"Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance","volume":"26","author":"Francis","year":"2003","journal-title":"Drug Saf."},{"key":"10.1016\/j.omton.2026.201226_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in cancer patients: a review","volume":"4","author":"Quesada","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201226_bib28","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","article-title":"Multiple sclerosis - Side effects of interferon beta therapy and their management","volume":"53","author":"Walther","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.omton.2026.201226_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/DDDT.S42138","article-title":"Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis","volume":"7","author":"Mahe","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omton.2026.201226_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12325-015-0212-6","article-title":"Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon beta-1a","volume":"32","author":"Ben-Amor","year":"2015","journal-title":"Adv. Ther."},{"key":"10.1016\/j.omton.2026.201226_bib31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201226_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/IJNRD.S30194","article-title":"Thrombotic microangiopathy associated with use of interferon-beta","volume":"5","author":"Olea","year":"2012","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"10.1016\/j.omton.2026.201226_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.msard.2016.09.002","article-title":"Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report","volume":"10","author":"Gerischer","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.omton.2026.201226_bib34","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201226_bib35","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1128\/JVI.77.16.8843-8856.2003","article-title":"Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity","volume":"77","author":"Obuchi","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201226_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040353","article-title":"Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus","volume":"4","author":"Kirn","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.omton.2026.201226_bib37","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.omton.2026.201226_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12020","article-title":"Intracranial AAV-IFN-beta gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model","volume":"11","author":"GuhaSarkar","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omton.2026.201226_bib39","first-page":"75","article-title":"Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.omton.2026.201226_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201226_bib41","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1038\/mtna.2015.54","article-title":"A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase","volume":"5","author":"Podetz-Pedersen","year":"2016","journal-title":"Mol Ther-Nucl Acids"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:22:26Z","timestamp":1783326146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926001025"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201226","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelial injury is a central driver of systemic IFN-\u03b2 toxicity and is reversible through Jak inhibition","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201226"}}